Aurion Biotech
Facts
- HQ
- United States
- Sectors
- Biotechnology
- Founded
- 2022
- Employees
- 116
- Stage
- Clinical-stage
- Total raised
- $81.4M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $26.1M · Apr 2022 SEC Form D
Jacob Colker reflects on Hubble Network raised $200M at a $1.6B valuation in LinkedIn roundup of Seattle wins
A LinkedIn article by Jacob Colker (published Sep 29, 2026) highlights recent Seattle achievements, including Hubble Network raising $200 million at a $1.6 billion valuation to connect ordinary Bluetooth devices. The piece frames these stories as reminders that the Seattle region is more influential than commonly perceived.
LogicGate opens Bellevue office for 25, names Diego Panama CEO and hires Seattle CMO and CFO as it pivots to AI
Chicago-based governance, risk and compliance software firm LogicGate is opening a Bellevue office for up to 25 employees and expects about 20 there by year-end while appointing Diego Panama as CEO and adding Seattle hires Michael Schultz (CMO) and David Rostov (CFO) as it shifts toward AI-focused products.
Gennev Founder Jill Angelo Steps Down After Acquisition; Aurion Biotech CEO Replaced Following Alcon Majority Stake; Temporal Adds New Leadership
Jill Angelo, founder and CEO of menopause startup Gennev, stepped down following its acquisition by Unified Women’s Healthcare, while Aurion Biotech replaced CEO Greg Kunst with Arnaud Lacoste after Alcon acquired a majority stake. Temporal also announced leadership additions with Jim Cyb as president and Sahir Azam as an independent board member.
GeekWire 200 Q1 2025: Highspot Leads as Helion Rises to No. 2 After $425M Funding; Truveta, Statsig, Protect AI Also Advance
The GeekWire 200 Q1 2025 update highlights rapidly growing Pacific Northwest tech startups, with Highspot retaining No. 1 and Helion rising to No. 2 after a $425 million funding round. Other notable movers include Truveta, Statsig, Protect AI, Carbon Robotics, and Stoke Space, reflecting dynamic shifts in the regional tech landscape.
Aurion Biotech Secures FDA Designations to Fast-Track Vision-Restoring Cell Therapy for Corneal Edema
Aurion Biotech received FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations to accelerate approval of its cell therapy for corneal edema, a vision-impairing disease. The company recently completed enrollment in a Phase 1/2 trial in the US and Canada and has approval to use the therapy in Japan.
Aurion Biotech Raises $120M to Advance Cell Therapy for Corneal Edema Affecting Millions
Aurion Biotech, a spinoff of CorneaGen, has raised $120 million to advance its cell therapy for treating corneal edema caused by endothelial dysfunction, a condition leading to impaired vision or blindness affecting about 4% of people over 40 in the U.S. The therapy uses cultured corneal cells from a single donor to treat multiple patients with a less complex procedure than corneal transplantation.
People
-
David Rostov Executive, Chief Financial Officer, Executive Officer
